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NOSRATOLA D. VAzIRI and KAI Hui LIANG
Division of Nephrology, Department of Medicine, University of California, Irvine, Irvine, California, USA
Hepatic HMG-CoA reductase gene expression during the course of
puromycin-induced nephrosis. Increased production and depressed catab-
olism of lipoproteins play major roles in the pathogenesis of hypercholes-
terolemia of nephrotic syndrome (NS). However, the effect, if any, of NS
on cholesterol biosynthetic capacity is uncertain. We examined the gene
expression of hepatic 3-hydroxy-3-methylglutaryl-C0A reductase (HMG-
CoAR, the rate limiting step in cholesterol biosynthesis) during the
induction and chronic phase of puromycin (PAN)-induced NS in rats. The
rats were randomized to NS (given i.p. puromycin aminonucleoside 130
mg/kg on day 1 and 60 mg/kg on day 14) and placebo-treated control
groups. Subgroups of animals were sacrificed at days 5, 10, 20 and 30. The
liver was harvested between 7 and 9 p.m. for measurements of HMG-
CoAR and actin mRNAs, HMG-CoAR enzymatic activity and microso-
mal cholesterol concentration. In separate experiments, subgroups of
animals with chronic NS (day 30) were studied in fed and 20-hour fasting
states. A marked but transient rise in hepatic HMG-CoAR mRNA and
HMG-CoAR enzymatic activity was observed following the onset and
exacerbation of proteinuria within a few days after each puromycin
injection. On each occasion, HMG-CoAR fell to the baseline level despite
persistent severe hypercholesterolemia. In an attempt to examine the
possible acute effect of PAN per Se, experiments were repeated before and
at short intervals (8 and 24 hr) after puromycin injection when proteinuria
was absent and the drug exposure prominent. The HMG-CoAR mRNA
and activity were virtually unchanged during this period, suggesting the
lack of an acute effect of puromycin. Twenty-hour fasting led to a marked
rise in HMG-CoAR mRNA and activity in animals with chronic NS but
not in the controls. Microsomal cholesterol remained unchanged and
comparable in the two groups at all points. Thus, the marked but transient
rise in hepatic HMG-CoAR gene expression observed during the induc-
tion phase and with fasting during the chronic phase of PAN-induced NS
may contribute to the generation and maintenance of hypercholesterol-
emia in this animal model.
Hypercholesterolemia is a nearly constant feature of NS [1—4]
and may be causally involved in the pathogenesis of the associated
progressive renal insufficiency and cardiovascular complications
[5—101. The nephrotic hyperlipidemia is marked by diffuse quan-
titative and qualitative abnormalities of plasma lipoproteins. For
instance, plasma concentrations of apoprotein B, LDL, VLDL,
intermediate density lipoproteins (IDL) and LPa are increased
while LDL-to-HDL and apoprotein C-Il to C-Ill ratios are
decreased in NS [11—14]. In addition, the proportion of choles-
terol to triglycerides and proportion of cholesterol, cholesterol
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esters and phospholipid to protein is increased in all lipoproteins
[12]. Moreover, the amounts per VLDL particle of apoproteins
A-I, C-Il and E (a receptor protein necessary for hepatic uptake
of IDL) are reduced in NS [14]. Likewise, the concentration of the
cardioprotective HDL-2 is reduced while that of HDL-3 is
elevated [151 and HDL composition is abnormal in this condition
[4].
The mechanism of nephrotic hypercholesterolemia is incom-
pletely understood. Increased production and reduced clearance!
catabolism of various lipoproteins have been convincingly dem-
onstrated in clinical and experimental NS [2—4, 16—191. However,
the available data on the hepatic metabolism of cholesterol have
been contradictory. Increased, [20—22] decreased [23] and normal
[24] rates of hepatic cholesterol biosynthesis have been reported
in NS by different investigators using 14C-acetate incorporation.
In a recent study [251 the enzymatic activities of the hepatic
HMG-CoAR (the rate limiting enzyme in cholesterol biosynthe-
sis) and cholesterol 7a-hydroxylase (the rate limiting enzyme in
cholesterol conversion to bile acids) were shown to be normal in
rats with established PAN-induced NS, suggesting that the asso-
ciated hypercholesterolemia is not due to a marked alteration of
hepatic cholesterol synthesis or degradation.
We hypothesized that cholesterol biosynthetic capacity may
rise, at least transiently, during the initial course of PAN-induced
NS to accommodate the increase in plasma cholesterol from
normal levels prior to onset of NS to the elevated values observed
thereafter. The present study was designed to test this hypothesis.
To this end, the hepatic HMG-CoAR mRNA and enzymatic
activity were quantitated longitudinally during the course of
induction and chronic phase of PAN-induced NS. The results
were compared with those obtained in the normal control group.
Methods
Study groups
Male Sprague-Dawley rats (Charles River Inc., Wilmington,
MA, USA) weighing 175 to 200 grams were used. They were fed
regular rat chow (Purina Mills Inc., Brentwood, MO, USA) and
kept in a climate-controlled and light-regulated space with 12-
hour light (500 lux) and dark ( 5 lux) cycles. The animals were
randomly placed into the NS and normal control (NL) groups.
Animals assigned to the NS group were given an intraperitorseal
(IP) injection of puromycin aminonucleoside (Sigma Inc., St.
Louis, MO, USA) 130 mg/kg on day 1. A second i.p. injection of
puromycin, 60 mg/kg, was administered on day 14. Animals placed
in the normal control (NL) group received i.p. injections of a
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placebo (5% dextrose solution) instead. Plasma concentrations of
albumin, creatinine and cholesterol and 24-hour urinary excre-
tions of protein and creatinine were determined regularly using
standard laboratory techniques.
In addition to the NS and the corresponding control groups
noted above, we studied a group of animals with diet-induced
hypercholesterolemia (DHC) gauged to approximate that ob-
served in the NS group. Animals placed in this group were fed a
rat chow fortified with 4% cholesterol, 5% lard and 2% sodium
cholate prepared by Purina Mills for six weeks. A group of normal
animals fed regular rat chow served as controls for this group.
Study design
Subgroups of animals were studied at baseline and on days 5,
10, 20 and 30 after the initial injections. These animals were
provided free access to food and water at all times. On each
occasion, animals were placed in metabolic cages for a 24-hour
urine collection. Blood samples were then obtained by orbital
sinus puncture, and animals were killed by decapitation. The liver
was removed immediately for measurements of microsomal cho-
lesterol and HMG-CoAR mRNA and enzyme activity.
In a separate set of experiments, animals with chronic NS (day
30) and their control counterparts were divided into two sub-
groups of which one was allowed free access to food and water
(fed group) while the others were provided with water alone and
rio food for 20 hours (fasting group). The animals were then
studied as described above.
In an attempt to discern the possible acute effect of puromycin
per se on hepatic HMG-CoAR, we studied a group of rats at
baseline and at short intervals (8 and 24 hr) after injection of
puromycin (130 mg/kg). This time interval was chosen because
during this period proteinuria was absent and drug exposure was
prominent.
Isolation of rat liver RNA
The animals were killed by decapitation between the hours of 7
to 9 p.m., and the liver was removed immediately. Total RNA was
prepared from I g of liver tissue by the guanidinium thiocyanate
extraction procedure as previously described [26]. Poly(A) RNA
was isolated by Oligo (dT)-cellulose chromatography (Gibco
BRL, MD, USA). The amount of mRNA was determined from
the absorbance at 260 nm using a spectrophotometer.
cDNA probes
The probe used for HMG-CoAR mRNA was a 4370 bp cDNA
to hamster HMG-CoAR mRNA (American Type Culture Collec-
tion). An 1100 bp cDNA of human 13-actin (American Type
Culture Collection) was used to control for possible variations in
the RNA load. The probes were labeled with [a-32P1 dCTP (3000
Ci/mmol, 10 mCi/ml, NEN Research Products, Boston, MA,
USA) by the random primer method (Promega Prime-A-Gene
system). The specific activities of the probes used for hybridization
were typically 1.6—3.5 X 108 cpm/jxg DNA.
Northern blot analyses
Fifteen microgram aliquots of Poly(A) RNA were denatured
in 2.2 M formaldehyde at 65°C for 15 minutes and run on 1.2%
agarose/2.2 formaldehyde gel at 80 V for two to three hours. RNA
was transferred to nylon filter (Zeta Probe, Bio-Rad Lab) by
Table 1. Plasma concentrations of creatinine, albumin and total
cholesterol, 24-hour urinary protein excretion, liver size, liver protein
content, liver total RNA and liver microsomal cholesterol in the chronic
nephrotic and normal control (NL) groups
Nephrotic group(N = 10)
NL group
(N = 10) P values
Urine protein mg/24 hr 228.00 18.40 7.10 0.06 0.001
Plasma albumin g/dl 2.20 0.22 3.70 0.20 0.001
Plasma cholesterol mg/dl 321.00 15.60 63.30 4.90 0.001
Plasma creatinine mg/dl 0.62 0.05 0.69 0.04 NS
Cr mI/mm 1.37 0.06 1.67 0.27 NS
Liver size g 12.80 0.40 10.30 0.30 0.001
Liver protein content g 1.89 0.20 1.52 0.30  0.01
Liver RNA content mg 62.60 2.10 51.90 1.90 0.001
Liver microsomal cholesterol 29.30 1.90 27.9 1.30 NS
nmol/mg protein
All data are expressed as mean SEM.
capillary blotting method in 6 X SSC
immobilized by UV irradiation.
buffer overnight and
Prehybridization was performed in a solution containing: 5 X
SSPE, 5 X Denhard's solution, 3% dextran sulfate and 0.5% SDS
and 100 jxg/ml of denatured herring sperm DNA at 65°C for two
hours.
Hybridization was performed in the same solution with probes
at 65°C overnight. Filters were washed twice in 2 x SSPEIO.5%
SDS solution at room temperature, twice in I X SSPEIO.5% SDS
at 37°C and twice in 0.1 X SSPE/0.5% SDS at 65°C, 15 minutes
each. The washed filters were exposed to the film at —80°C for
periods ranging from two to five hours for actin and three to four
days for HMG-CoAR. The autoradiographs were scanned with a
laser densitometer (PD 1211, Molecular Dynamics, Sunnyvale,
CA, USA) to determine relative mRNA levels. The values
obtained for actin were used as internal control.
Measurements of HMG-CoAR activity and microsomal cholesterol
Lysosome-free hepatic microsomes were prepared by differen-
tial ultracentrifugation [27, 28]. The protein concentrations of the
microsomal suspensions were measured using a Bio-Rad Kit
(Bio-Rad Lab, Inc., Hercules, CA, USA). The HMG-CoAR
activity was determined according to the method of Simonet and
Ness [29]. Hepatic microsomal cholesterol was extracted and
assayed as described previously [30].
Statistical analyses
Analysis of variance (ANOVA), Duncan's multiple-range test,
Student's I-test and regression analysis were used in statistical
evaluation of the data as appropriate. Data are expressed as mean
SEM. P values equal to or less than 0.05 were considered
significant.
Results
General data
Data are depicted in Table 1. As expected, animals with chronic
NS (30 days) showed heayv proteinuria, hypoalbuminemia and
marked hypercholesterolemia. However, no significant difference
was found in the serum creatinine concentration or creatinine
clearance between the NS and the control groups. The nephrotic
group exhibited significant hepatic hypertrophy as evidenced by
greater size, total protein and RNA contents of the liver as
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compared with the normal control group. No significant difference
was found in microsomal cholesterol concentration between the
two groups.
Changes in plasma concentrations of albumin and cholesterol
and urinary protein excretion rates during the study period are
depicted in Figure 1. As can be seen, the onset of the rise in
plasma cholesterol coincided with the onset of proteinuria and the
decline in serum albumin concentration. Accordingly, the results
could not dissect the pathogenetic role of proteinuria from that of
hypoalbuminemia in triggering the rise in cholesterol concentra-
tion.
HMG-CoAR levels
Longitudinal data. Data are shown in Figures 2 and 3. Serial
measurements of hepatic HMG-CoAR mRNA levels showed a
significant rise above the baseline value within a few days after
Time, days
Fig. 2. Longitudinal measurements of HMG-CoA reductase mRNA (nor-
malized against corresponding actin mRNA) and enzymatic activity in the
nephrotic N = 6) and normal control (•, N = 6)groups. Data are given
as mean SEM. *p < 0.05 (multiple measure ANOVA and Duncan's
multiple-range test).
each of the two injections of puromycin aminonucleoside with a
subsequent decline to the baseline level. The corresponding
HMG-CoAR enzymatic activity measurements paralleled the
pattern found with mRNA values. Serum cholesterol concentra-
tion rose markedly by approximately fivefold within five days after
initial injection of puromycin, and remained elevated throughout
the course of the study period despite the restoration of hepatic
HMG-CoAR levels to the normal level (Figs. 1 and 2). These
observations suggest that increased hepatic HMG-CoAR may be
necessary for the generation of hypercholesterolemia. The data
further suggest that normal rates of HMG-CoAR expression may
be sufficient for the maintenance of hypercholesterolemia in
chronic PAN-induced NS under steady-state conditions.
HMG-CoAR transcript and enzymatic activity obtained at
baseline and at short intervals (8 and 24 hr) after puromycin
injection during which time proteinuria was absent showed virtu-
ally no change in either parameter during this period. This
observation tends to exclude a possible acute effect of puromycin
per se on hepatic HMG-CoAR gene expression (Fig. 4).
Chronic NS. No significant difference was found in hepatic
HMG-CoAR mRNA levels between animals with chronic nephro-
sis (day 30) and the normal control group given free access to food
and water. Likewise, hepatic HMG-CoAR enzymatic activity was
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Fig. 1. Changes of plasma concentrations of cholesterol and albumin and
urinay protein excretion in the nephrotic (, N = 6) and normal control (S,N = 6) groups during the study period. Data are given as mean and SEM.
< 0.001 (multiple measure ANOVA and Duncan's multiple-range test).
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Fig. 3. A representative autoradiograph of the Northern blot of hepatic
HMG-CoAR and the corresponding actin in the normal control (NL, lane 1)
and the nephrotic animals (NS) at days 5 (lane 2), 10 (lane 3), 20 (lane 4),
and 30 (lane 5) in the course of induction of nephrosis with two puromycin-
aminonucleoside injections given on days I and 14. Po1y(A)RNA (15
tg/1ane) was isolated from liver as described in the Methods section, and
separated by electrophoresis on 1.2% agarose/2.2 M formaldehyde gel.
mRNA was transferred to a nylon filter and hybridized with the 32P-
labeled full-length eDNA to hamster HMG-CoAR mRNA and 1.1 Kb
eDNA to human -actin mRNA used to control for possible variations in
the loading dose.
similar in the two groups while on no food restriction. Comparison
of data obtained after a 20-hour fasting period showed a signifi-
cant rise in hepatic HMG-CoAR mRNA and enzymatic activity in
the NS group but not in the normal control group (Figs. 5 and 6).
Diet-induced hypercholestrolemia. Data are depicted in Table 2
and Figure 7. Animals with diet-induced hypercholesterolemia
exhibited a marked elevation of serum cholesterol concentration
approximating that seen in the NS group. However, in contrast to
animals with chronic NS, the animals with diet-induced hypercho-
lesterolemia showed massive accumulation of cholesterol in he-
patic tissue and a marked reduction in hepatic HMG-CoAR
transcript (Fig. 7). This observation is consistent with that re-
ported by other investigators [311.
Correlations
A strong correlation was found between plasma cholesterol
concentration and the extent of proteinuria in the entire study
population (r = 0.84, P < 0.001). A significant inverse correlation
was noted between plasma concentrations of cholesterol and
albumin (r =
—0.61, P < 0.001). The HMG-CoA reductase
activity measurements significantly correlated with the corre-
sponding HMG-CoA reductase mRNA measurements (r = 0.72,
P < 0.001; Figs. 8 and 9).
Discussion
Although much is known about the effects of NS on the
composition and metabolism of plasma lipoproteins, certain basic
issues concerning cholesterol metabolism remain uncertain. In
mammals the liver plays an important role in cholesterol ho-
meostasis through coordinated regulation of the following meta-
bolic pathways: (a) internalization of circulating cholesterol-
containing particles through various LDL receptors; (b) the
catabolic pathway involving cholesterol conversion to bile acids
and their excretion in the bile; and finally (c) endogenous
biosynthesis of cholesterol from acetate [321. Several studies have
convincingly demonstrated the role of impaired hepatic lipopro-
tein uptake in the pathogenesis of hyperlipidemia of NS [2—4, 16,
Fig. 4. I. Representative Northern blot of hepatic HMG-CoA reductase and
the corresponding actin obtained at baseline (A) and at eight hours (B) and
24 hours (C) after i.p. injection of puromycin (130 mg/kg). II. Comparison
of hepatic HMG-CoA reductase/actin mRNA and enzymatic activity
obtained at baseline and at eight hours and 24 hours after puromycin
injection (N = 4 in each group). Data are given as mean SEM.
18]. With regards to the cholesterol catabolism, Thabet et al have
recently demonstrated a normal rate of bile acid secretion and a
normal hepatic tissue activity of cholesterol 7cs-hydroxylase (the
rate limiting enzyme of bile acid production) in rats with PAN-
induced NS [251. These findings have been recently confirmed in
our laboratory (unpublished data). Thus, NS does not appear to
affect cholesterol conversion to and hepatic excretion of bile acids.
However, the available data on the effect of NS on hepatic
cholesterol biosynthesis are limited and contradictory. Increased,
decreased and normal cholesterol production rates have been
reported in earlier studies employing labeled acetate incorpora-
tion technique [20—24].
HMG-CoAR is the rate limiting enzyme in cholesterol biosyn-
thesis. The hepatic HMG-CoAR activity has been shown to
closely parallel the rate of hepatic cholesterol biosynthesis under
a variety of experimental conditions and at a broad range of
cholesterol biosynthetic rates [33, 34]. In a recent study, Thabet et
al showed that hepatic HMG-CoAR enzymatic activity is normal
in rats with established PAN-induced NS [25]. The present study
was designed to examine hepatic HMG-CoAR gene expression
during the induction and chronic phase of PAN-induced NS. The
results showed a significant but transient rise in HMG-CoAR
mRNA within a few days after each of the two injections of
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Table 2. Plasma cholesterol and albumin concentrations, creatinine
clearance (Cr), 24-hour urinary protein excretion and hepatic tissue
cholesterol concentration in the diet-induced hypercholesterolemic
(DHC) and normal control (NL) groups
DHC group
(N = 6)
NL group
(N = 6) P values
Plasma cholesterol 302 43.7 56.6 6.8  0.001
mg/dl
Plasma albumin 3.36 0.15 3.36 0.22 NS
gidI
Urine protein 9.07 1.1 7.13 1.7 NS
mg/24 hr
Ccr mI/mm 1.21 0.14 1.57 0.37 NS
Liver cholesterol concentration 30.7 2.3 1.9 0.16  0.001
mg/g wet tissue
Liver size g 17.9 1.8 10.1 0.72 0.001
Fig. 6. Representative Northern blot of hepatic HMG-CoAR and the coire-
sponding actin in the normal (NL) and chronic nephrotic (NS) animals in
fed and 20-hour fasting states.
Fig. 7. A. Representative Northern blot of hepatic HMG-CoAR and the
corresponding actin in a normal control (NL) rat and a diet-induced
hypercholesterolemic (DHC) rat. B. Comparison of hepatic HMG-CoA
reductase/actin mRNA in NL and DHC groups (N = 6 in each group).
Data are given as mean SEM. P < 0.001.
levels within 8 to 24 hours after puromycin injection, suggesting
the lack of an acute effect of the drug on gene expression of this
puromycin paralleling the onset and exacerbation of proteinuria enzyme. Nonetheless, a possible delayed and NS-independent
with the first and second injections. This was accompanied by effect of puromycin cannot be excluded by these experiments with
parallel changes in HMG-CoAR enzymatic activity along with
rising plasma cholesterol concentration. On each occasion HMG-
CoA levels returned to normal values despite persistent hyper-
cholesterolemia. We found no significant change in HMG-CoAR
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All data are expressed as mean SEM.
Fed Fasting
Fig. 5. Comparison of hepatic HMG-CoA reductase/actin mRNA and
enzymatic activity in the normal control (U N = 6) and chronic nephrotic(, N = 6) rats in fed and 20-hour fasting states. Data are given as mean
SEM. *P < 0.001.
certainty.
In spite of severe and persistent hypercholesterolemia, hepatic
HMG-CoAR mRNA and activity were normal in fed animals with
chronic NS. The latter observation confirms the results reported
HMG-CoA
NL NS NL NS
—28S
—1 8S
Actin
Fed Fasting
A
NL DHC
1-1MG-CoAR
Actin
4
B
—I-
4— 28S
4- lBS
1
NL DHC
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Fig. 8. Relationship of plasma cholesterol concentration with (A) plasma
albumin concentration and (B) urinaiy protein excretion in the entire study
population, that is, normal controls (•) and nephrotic 'U) rats obtained at
different time periods.
by Thabet et a! [25]. The transient rise in hepatic HMG-CoAR
expression during the induction and its subsequent decline to
basal levels in the chronic phase of proteinuria suggests that a
heightened hepatic cholesterol biosynthetic capacity must contrib-
ute to the initial rise of plasma cholesterol concentration in this
model. Moreover, the presence of severe hypercholesterolemia in
the face of normal hepatic HMG-CoAR levels in the fed animals
with chronic nephrotic syndrome indicates that under steady state
condition, persistent elevation of cholesterol biosynthetic capacity
is not necessary for the maintenance of hypercholesterolemia in
PAN-induced NS. This viewpoint is indirectly supported by an
earlier study demonstrating normal rates of production and biliary
excretion of bile acids in rats with puromycin-induced NS [25].
Since bile acid production is the principal pathway of cholesterol
elimination, its demonstrated normality in this model of NS
indicates that an increased cholesterol biosynthesis must occur to
accommodate the initial rise of plasma cholesterol. It further
suggests that once attained, hypercholesterolemia can be sus-
tained at a normal rate of cholesterol biosynthesis during the
steady state chronic condition.
Our rats with diet-induced hypercholesterolemia exhibited a
marked reduction in hepatic HMG-CoAR gene expression, con-
firming previous observations [31]. In contrast, despite an equally
severe hypercholesterolemia, rats with chronic NS showed normal
hepatic HMG-CoAR values. This observation suggests that nor-
mal hepatic HMG-CoAR values in chronic NS may, in fact,
represent an inappropriate elevation for the degree of the asso-
ciated hypercholesterolemia. It should be noted that while plasma
cholesterol concentrations in the chronic NS and diet-induced
hypercholesterolemic rats were elevated to an approximately
equal extent, their hepatic tissue cholesterol concentrations were
greatly disparate, that is, normal in the chronic NS and markedly
elevated in the diet-induced hypercholesterolemic rats. Since
feedback regulation of HMG-CoAR gene expression [32—34] is
primarily linked to the intracellular cholesterol concentration, its
inhibition in the diet-induced hypercholesterolemia but not in the
chronic NS is physiologically understandable. Thus, the apparent
failure of the rats with chronic NS to down regulate hepatic
HMG-CoAR despite severe hypercholesterolemia appears to be
linked to the impaired hepatocyte uptake of cholesterol from the
circulation. It is of interest that hepatic HMG-CoAR level rose
significantly with fasting in animals with chronic NS but not in the
normal controls. This observation suggests that hepatic choles-
terol biosynthetic capacity can be heightened, as needed, to
sustain hypercholesterolemia when dietary intake is reduced in
rats with chronic puromycin-induced NS.
Recently, Joles et a! reported increased synthesis of nonsaponi-
fiable lipid in the carcass of rats with hereditary analbuminemia
using 3H20 incorporation [35]. In conjunction with the present set
of experiments, we attempted to determine HMG-CoAR mRNA
in the carcass of the study groups. However, the results were
inconclusive and as such failed to elucidate the effect, if any, of NS
on cholesterol biosynthetic capacity of these extrahepatic tissues
in this model of NS.
In conclusion, the rise in cholesterol concentration was associ-
ated with a significant but transient increase in hepatic HMG-
CoAR gene expression during the induction of puromycin-in-
duced NS. Despite persistent hypercholesterolemia, hepatic
HMG-CoAR returned to baseline during the steady-state chronic
condition. Interestingly, prolonged fasting led to a significant
up-regulation of 1-IMG-CoAR in rats with chronic PAN-induced
NS. These findings suggest that transient increases in hepatic
HMG-CoAR gene expression during the induction phase and
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Fig. 9. Relationship of hepatic HMG-CoA reductase mRNA and enzymatic
activity in the entire study population of normal control (•) and nephrotic
•) animals obtained at different time points. r = 0.72; P < 0.001.
r= 0.84; P < 0.001
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with food restriction during the chronic phase of PAN-induced NS
may contribute to the genesis and maintenance of hypercholes-
terolemia in this model. Further studies are needed to substanti-
ate these findings in other models of NS.
Reprint requests to N.D. Vaziri, M.D., Division of Nephrology, UCI
Medical Center, 101 The City Drive, Orange, California 92668, USA.
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